Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Filippo Cipriani"'
Autor:
Agostino Fortunato, Debora Antonini, Edoardo Vincenzo Savarino, Francesca Racca, Roberto Penagini, Francesca Fanelli, Jean Pierre Saab, Filippo Cipriani, Roberta Giodice, Filippo Rumi, Americo Cicchetti
Publikováno v:
Frontiers in Gastroenterology, Vol 3 (2024)
BackgroundEosinophilic esophagitis (EoE) is a chronic and progressive type 2 inflammatory disease affecting the esophagus. Its prevalence has increased in recent years due to increased awareness, evolving clinical guidelines, and heightened sensitivi
Externí odkaz:
https://doaj.org/article/4f39d6b914c34372bdf2ecdef9ac3a03
Publikováno v:
ACS Omega, Vol 4, Iss 6, Pp 10818-10827 (2019)
Externí odkaz:
https://doaj.org/article/2180e4b28f1d429e9ed4084ed7ccadb4
Publikováno v:
Global & Regional Health Technology Assessment, Vol 7, Iss 1 (2020)
Background and research question: Label extension for treatments and the relevant disease cross-coverage may produce an economic benefit. This paper assesses this benefit for dupilumab in the perspective of the Italian National Health Service. Dupilu
Externí odkaz:
https://doaj.org/article/c9b856ab3d2443f6a3829b4ae2c68333
Autor:
Iria Neri, Elena Galli, Ilaria Baiardini, Mario Picozza, Ana B Rossi, Paolo Matruglio, Devis Moretti, Filippo Cipriani
Publikováno v:
Journal of Asthma and Allergy.
Iria Neri,1 Elena Galli,2 Ilaria Baiardini,3,4 Mario Picozza,5,6 Ana B Rossi,7 Paolo Matruglio,8 Devis Moretti,8 Filippo Cipriani8 1Dermatology Unit, IRCCS Azienda Ospedaliero Universitaria Bologna, University of Bologna, Bologna, Italy; 2UOS Immuno-
Autor:
Katharina Hansel, Devis Moretti, Anna Belloni Fortina, Luca Stingeni, Filippo Cipriani, Ilaria Baiardini
Publikováno v:
Journal of Asthma and Allergy
Journal of Asthma and Allergy, Vol Volume 14, Pp 919-928 (2021)
Journal of Asthma and Allergy, Vol Volume 14, Pp 919-928 (2021)
Luca Stingeni,1 Anna Belloni Fortina,2 Ilaria Baiardini,3,4 Katharina Hansel,1 Devis Moretti,5 Filippo Cipriani5 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 2Unit of Dermatology, Department of Medi
Autor:
Veronica Della Latta, Ilenia Iaia, Mauro Giacca, Lorena Zentilin, Tiziana Cervelli, Filippo Cipriani, Alvaro Galli, Maria Serena Milella
Publikováno v:
Molecular Biotechnology. 63:156-165
Adeno-associated virus (AAV) is a small, non-enveloped virus used as vector in gene therapy, mainly produced in human cells and in baculovirus systems. Intense studies on these platforms led to the production of vectors with titers between 103 and 10
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 17, Iss 3 (2016)
BACKGROUND: Radioiodine ablation is an adjuvant procedure used to treat patients with differentiated thyroid cancer. For ablation to be successful, patients must have elevated levels of thyroid stimulating hormone (TSH). This can be achieved by withh
Externí odkaz:
https://doaj.org/article/ccb4191942b84f6cb01afd4daac29742
Autor:
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 9, Iss 1S, Pp 3-10 (2008)
Introduction: the impact of cervical cancer prevention, in particular through HPV female vaccination, has been published for many countries at the national level. However, to our knowledge no attempt has been made to address the impact at a regional
Externí odkaz:
https://doaj.org/article/13f265baf2fc40a39822058a034e3762
Publikováno v:
ACS Omega
ACS Omega, Vol 4, Iss 6, Pp 10818-10827 (2019)
ACS Omega, Vol 4, Iss 6, Pp 10818-10827 (2019)
A cellular coating based on hydrophobic interactions of an elastin-like recombinamer (ELR) with the cell membrane is presented. It is well-documented that biophysical properties such as net charge, hydrophobicity, and protein-driven cell-ligand (inte
Autor:
Annamaria Offidani, Ana B. Rossi, Luca Stingeni, Yufang Lu, Devis Moretti, Zhen Chen, Iria Neri, Filippo Cipriani
Publikováno v:
Italian journal of dermatology and venereology. 157(1)
BACKGROUND In multiple phase 3 trials, dupilumab improved signs, symptoms (including pruritus), and quality-of-life (QoL) in adults with moderate-to-severe atopic dermatitis (AD). In Italy, dupilumab received innovation status but is currently only r